http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 29 May 2026 16:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SCYNEXIS+INC++++++++++++++For%3A+May+28/26574887.html si-local-file:///var/storage/secattach/20260529/26574887.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SCYNEXIS+INC++++++++++++++For%3A+May+28/26574887.html Fri, 29 May 2026 16:02:00 -0400 O.00000088 SCYX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SCYNEXIS+INC++++++++++++++For%3A+May+28/26574887.html si-local-file:///var/storage/secattach/20260529/26574887.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SCYNEXIS+INC++++++++++++++For%3A+May+28/26574887.html Fri, 29 May 2026 16:02:00 -0400 O.00000088 SCYX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SCYNEXIS+INC++++++++++++++For%3A+May+19/26542022.html si-local-file:///var/storage/secattach/20260522/26542022.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SCYNEXIS+INC++++++++++++++For%3A+May+19/26542022.html Fri, 22 May 2026 16:20:00 -0400 O.00000088 SCYX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SCYNEXIS+INC++++++++++++++For%3A+May+19/26542022.html si-local-file:///var/storage/secattach/20260522/26542022.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SCYNEXIS+INC++++++++++++++For%3A+May+19/26542022.html Fri, 22 May 2026 16:20:00 -0400 O.00000088 SCYX http://www.streetinsider.com/Stock+Splits/SCYNEXIS+implements+one-for-eight+reverse+stock+split/26541818.html <p>SCYNEXIS Inc. (NASDAQ: SCYX) announced it will conduct a one-for-eight reverse stock split of its common stock, effective at 4:05 p.m. ET on May 29, 2026.</p> <p>The biotechnology company's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market starting June 1, 2026, under the existing symbol "SCYX" with a new CUSIP number 811292 309.</p> <p>Stockholders approved the reverse split at a special meeting held May 19, 2026, with the final ratio determined by the company's board of directors. The action is intended to meet Nasdaq Capital Market's minimum bid price requirement for continued listing.</p> <p>Under the reverse split, every http://www.streetinsider.com/Stock+Splits/SCYNEXIS+implements+one-for-eight+reverse+stock+split/26541818.html Fri, 22 May 2026 16:15:23 -0400 A.50216777 O.00000088 O.54516537 SCYX http://www.streetinsider.com/Stock+Splits/SCYNEXIS+implements+one-for-eight+reverse+stock+split/26541818.html <p>SCYNEXIS Inc. (NASDAQ: SCYX) announced it will conduct a one-for-eight reverse stock split of its common stock, effective at 4:05 p.m. ET on May 29, 2026.</p> <p>The biotechnology company's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market starting June 1, 2026, under the existing symbol "SCYX" with a new CUSIP number 811292 309.</p> <p>Stockholders approved the reverse split at a special meeting held May 19, 2026, with the final ratio determined by the company's board of directors. The action is intended to meet Nasdaq Capital Market's minimum bid price requirement for continued listing.</p> <p>Under the reverse split, every http://www.streetinsider.com/Stock+Splits/SCYNEXIS+implements+one-for-eight+reverse+stock+split/26541818.html Fri, 22 May 2026 16:15:23 -0400 A.50216777 O.00000088 O.54516537 SCYX http://www.streetinsider.com/Stock+Splits/SCYNEXIS+implements+one-for-eight+reverse+stock+split/26541818.html <p>SCYNEXIS Inc. (NASDAQ: SCYX) announced it will conduct a one-for-eight reverse stock split of its common stock, effective at 4:05 p.m. ET on May 29, 2026.</p> <p>The biotechnology company's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market starting June 1, 2026, under the existing symbol "SCYX" with a new CUSIP number 811292 309.</p> <p>Stockholders approved the reverse split at a special meeting held May 19, 2026, with the final ratio determined by the company's board of directors. The action is intended to meet Nasdaq Capital Market's minimum bid price requirement for continued listing.</p> <p>Under the reverse split, every http://www.streetinsider.com/Stock+Splits/SCYNEXIS+implements+one-for-eight+reverse+stock+split/26541818.html Fri, 22 May 2026 16:15:23 -0400 A.50216777 O.00000088 O.54516537 SCYX http://www.streetinsider.com/Stock+Splits/SCYNEXIS+implements+one-for-eight+reverse+stock+split/26541818.html <p>SCYNEXIS Inc. (NASDAQ: SCYX) announced it will conduct a one-for-eight reverse stock split of its common stock, effective at 4:05 p.m. ET on May 29, 2026.</p> <p>The biotechnology company's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market starting June 1, 2026, under the existing symbol "SCYX" with a new CUSIP number 811292 309.</p> <p>Stockholders approved the reverse split at a special meeting held May 19, 2026, with the final ratio determined by the company's board of directors. The action is intended to meet Nasdaq Capital Market's minimum bid price requirement for continued listing.</p> <p>Under the reverse split, every http://www.streetinsider.com/Stock+Splits/SCYNEXIS+implements+one-for-eight+reverse+stock+split/26541818.html Fri, 22 May 2026 16:15:23 -0400 A.50216777 O.00000088 O.54516537 SCYX http://www.streetinsider.com/Press+Releases/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html <p align="justify">JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-8, effective at 4:05 p.m. ET on May 29, 2026.</p> <p align="justify">SCYNEXIS’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on June 1, 2026 under SCYNEXIS’s existing trading symbol “SCYX” with a new CUSIP number, 811292 309.</p> http://www.streetinsider.com/Press+Releases/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html Fri, 22 May 2026 16:15:00 -0400 A.50216777 O.00000088 O.54516537 SCYX http://www.streetinsider.com/Press+Releases/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html <p align="justify">JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-8, effective at 4:05 p.m. ET on May 29, 2026.</p> <p align="justify">SCYNEXIS’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on June 1, 2026 under SCYNEXIS’s existing trading symbol “SCYX” with a new CUSIP number, 811292 309.</p> http://www.streetinsider.com/Press+Releases/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html Fri, 22 May 2026 16:15:00 -0400 A.50216777 O.00000088 O.54516537 SCYX http://www.streetinsider.com/Press+Releases/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html <p align="justify">JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-8, effective at 4:05 p.m. ET on May 29, 2026.</p> <p align="justify">SCYNEXIS’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on June 1, 2026 under SCYNEXIS’s existing trading symbol “SCYX” with a new CUSIP number, 811292 309.</p> http://www.streetinsider.com/Press+Releases/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html Fri, 22 May 2026 16:15:00 -0400 A.50216777 O.00000088 O.54516537 SCYX http://www.streetinsider.com/Press+Releases/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html <p align="justify">JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-8, effective at 4:05 p.m. ET on May 29, 2026.</p> <p align="justify">SCYNEXIS’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on June 1, 2026 under SCYNEXIS’s existing trading symbol “SCYX” with a new CUSIP number, 811292 309.</p> http://www.streetinsider.com/Press+Releases/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html Fri, 22 May 2026 16:15:00 -0400 A.50216777 O.00000088 O.54516537 SCYX http://www.streetinsider.com/Globe+Newswire/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html <p align="justify">JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-8, effective at 4:05 p.m. ET on May 29, 2026.</p> <p align="justify">SCYNEXIS’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on June 1, 2026 under SCYNEXIS’s existing trading symbol “SCYX” with a new CUSIP number, 811292 309.</p> http://www.streetinsider.com/Globe+Newswire/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html Fri, 22 May 2026 16:15:00 -0400 A.50216777 O.00000088 O.54516537 SCYX http://www.streetinsider.com/Globe+Newswire/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html <p align="justify">JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-8, effective at 4:05 p.m. ET on May 29, 2026.</p> <p align="justify">SCYNEXIS’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on June 1, 2026 under SCYNEXIS’s existing trading symbol “SCYX” with a new CUSIP number, 811292 309.</p> http://www.streetinsider.com/Globe+Newswire/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html Fri, 22 May 2026 16:15:00 -0400 A.50216777 O.00000088 O.54516537 SCYX http://www.streetinsider.com/Globe+Newswire/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html <p align="justify">JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-8, effective at 4:05 p.m. ET on May 29, 2026.</p> <p align="justify">SCYNEXIS’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on June 1, 2026 under SCYNEXIS’s existing trading symbol “SCYX” with a new CUSIP number, 811292 309.</p> http://www.streetinsider.com/Globe+Newswire/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html Fri, 22 May 2026 16:15:00 -0400 A.50216777 O.00000088 O.54516537 SCYX http://www.streetinsider.com/Globe+Newswire/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html <p align="justify">JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-8, effective at 4:05 p.m. ET on May 29, 2026.</p> <p align="justify">SCYNEXIS’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on June 1, 2026 under SCYNEXIS’s existing trading symbol “SCYX” with a new CUSIP number, 811292 309.</p> http://www.streetinsider.com/Globe+Newswire/SCYNEXIS+Announces+One-for-Eight+Reverse+Stock+Split/26541815.html Fri, 22 May 2026 16:15:00 -0400 A.50216777 O.00000088 O.54516537 SCYX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SCYNEXIS+INC+++++++++++++++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26502728.html si-local-file:///var/storage/secattach/20260515/26502728.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SCYNEXIS+INC+++++++++++++++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26502728.html Fri, 15 May 2026 12:22:00 -0400 O.00000088 SCYX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SCYNEXIS+INC+++++++++++++++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26502728.html si-local-file:///var/storage/secattach/20260515/26502728.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SCYNEXIS+INC+++++++++++++++++++++++++++Filed+by%3A+CVI+Investments%2C+Inc./26502728.html Fri, 15 May 2026 12:22:00 -0400 O.00000088 SCYX http://www.streetinsider.com/Earnings/Scynexis+%28SCYX%29+Misses+Q1+EPS+by+29c/26469851.html <p>Scynexis (NASDAQ: SCYX) reported Q1 EPS of ($0.42), $0.29 worse than the analyst estimate of ($0.13).</p><p>For earnings history and earnings-related data on Scynexis (SCYX) <a href="http://www.streetinsider.com/ec_earnings.php?q=SCYX">click here</a>.</p> http://www.streetinsider.com/Earnings/Scynexis+%28SCYX%29+Misses+Q1+EPS+by+29c/26469851.html Mon, 11 May 2026 16:35:27 -0400 SCYX http://www.streetinsider.com/Press+Releases/SCYNEXIS+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26469507.html <ul type="disc"><li>Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)<br/><br/></li><li>A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027<br/><br/></li><li>Completed a private placement with net proceeds of approximately $37.2 million, after deducting placement agent fees and other transaction related expenses, with certain new and existing institutional and accredited investors. Approximately $24 million of the proceeds were received on March 31st with the balance received on April 1st<br/><br/></li><li>SCYNEXIS http://www.streetinsider.com/Press+Releases/SCYNEXIS+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26469507.html Mon, 11 May 2026 16:23:00 -0400 A.06822034 A.50216777 O.00000088 O.20026344 O.54516537 SCYX http://www.streetinsider.com/Press+Releases/SCYNEXIS+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26469507.html <ul type="disc"><li>Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)<br/><br/></li><li>A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027<br/><br/></li><li>Completed a private placement with net proceeds of approximately $37.2 million, after deducting placement agent fees and other transaction related expenses, with certain new and existing institutional and accredited investors. Approximately $24 million of the proceeds were received on March 31st with the balance received on April 1st<br/><br/></li><li>SCYNEXIS http://www.streetinsider.com/Press+Releases/SCYNEXIS+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26469507.html Mon, 11 May 2026 16:23:00 -0400 A.06822034 A.50216777 O.00000088 O.20026344 O.54516537 SCYX http://www.streetinsider.com/Press+Releases/SCYNEXIS+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26469507.html <ul type="disc"><li>Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)<br/><br/></li><li>A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027<br/><br/></li><li>Completed a private placement with net proceeds of approximately $37.2 million, after deducting placement agent fees and other transaction related expenses, with certain new and existing institutional and accredited investors. Approximately $24 million of the proceeds were received on March 31st with the balance received on April 1st<br/><br/></li><li>SCYNEXIS http://www.streetinsider.com/Press+Releases/SCYNEXIS+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26469507.html Mon, 11 May 2026 16:23:00 -0400 A.06822034 A.50216777 O.00000088 O.20026344 O.54516537 SCYX http://www.streetinsider.com/Press+Releases/SCYNEXIS+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26469507.html <ul type="disc"><li>Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)<br/><br/></li><li>A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027<br/><br/></li><li>Completed a private placement with net proceeds of approximately $37.2 million, after deducting placement agent fees and other transaction related expenses, with certain new and existing institutional and accredited investors. Approximately $24 million of the proceeds were received on March 31st with the balance received on April 1st<br/><br/></li><li>SCYNEXIS http://www.streetinsider.com/Press+Releases/SCYNEXIS+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26469507.html Mon, 11 May 2026 16:23:00 -0400 A.06822034 A.50216777 O.00000088 O.20026344 O.54516537 SCYX http://www.streetinsider.com/Press+Releases/SCYNEXIS+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26469507.html <ul type="disc"><li>Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)<br/><br/></li><li>A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027<br/><br/></li><li>Completed a private placement with net proceeds of approximately $37.2 million, after deducting placement agent fees and other transaction related expenses, with certain new and existing institutional and accredited investors. Approximately $24 million of the proceeds were received on March 31st with the balance received on April 1st<br/><br/></li><li>SCYNEXIS http://www.streetinsider.com/Press+Releases/SCYNEXIS+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26469507.html Mon, 11 May 2026 16:23:00 -0400 A.06822034 A.50216777 O.00000088 O.20026344 O.54516537 SCYX http://www.streetinsider.com/Press+Releases/SCYNEXIS+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26469507.html <ul type="disc"><li>Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)<br/><br/></li><li>A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027<br/><br/></li><li>Completed a private placement with net proceeds of approximately $37.2 million, after deducting placement agent fees and other transaction related expenses, with certain new and existing institutional and accredited investors. Approximately $24 million of the proceeds were received on March 31st with the balance received on April 1st<br/><br/></li><li>SCYNEXIS http://www.streetinsider.com/Press+Releases/SCYNEXIS+Reports+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26469507.html Mon, 11 May 2026 16:23:00 -0400 A.06822034 A.50216777 O.00000088 O.20026344 O.54516537 SCYX